

Jonathan A Ledermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8999932/publications.pdf>

Version: 2024-02-01

94
papers

17,538
citations

87886

38
h-index

48312

88
g-index

94
all docs

94
docs citations

94
times ranked

14009
citing authors

#	ARTICLE	IF	CITATIONS
1	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164.	27.0	1,860
2	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496.	27.0	1,843
3	Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1382-1392.	27.0	1,595
4	Ovarian cancer. <i>Lancet</i> , The, 2014, 384, 1376-1388.	13.7	1,491
5	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
6	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	13.7	1,261
7	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 852-861.	10.7	1,237
8	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 12-39.	2.5	859
9	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 928-936.	10.7	661
10	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 2-30.	2.5	515
11	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 295-309.	10.7	426
12	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1579-1589.	10.7	380
13	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1273-1285.	10.7	305
14	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1066-1074.	13.7	216
15	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	10.7	215
16	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3798-3804.	1.6	203
17	Homologous recombination deficiency and ovarian cancer. <i>European Journal of Cancer</i> , 2016, 60, 49-58.	2.8	193
18	Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 229-239.	3.2	189

#	ARTICLE	IF	CITATIONS
19	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018, 119, 1401-1409.	6.4	175
20	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.6	167
21	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015, 28, 1101-1122.	5.5	164
22	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIg phase 3 randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 2084-2095.	13.7	142
23	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2257-2269.	1.6	135
24	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 1075-1085.	6.4	133
25	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017, 23, 4086-4094.	7.0	114
26	Targeted Therapies for Ovarian Cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 139-152.	2.8	95
27	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Mucinous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S14-S19.	2.5	87
28	Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017, 8, 43653-43661.	1.8	85
29	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a <i>BRCA</i> mutation: Overall survival adjusted for postprogression poly(adenosine) Tj ETQq1 1 0.784314 rgBT7k Overlo	1.6	75
30	Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT. <i>Journal of Clinical Oncology</i> , 2007, 25, 4187-4193.	1.6	75
31	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a <i>BRCA</i> mutation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6002-6002.	1.6	75
32	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984975.	3.2	70
33	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	10.7	70
34	Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. <i>Clinical Cancer Research</i> , 2013, 19, 5227-5239.	7.0	63
35	Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials. <i>Cancer</i> , 2015, 121, 1737-1746.	4.1	59
36	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 115, 1313-1320.	6.4	52

#	ARTICLE	IF	CITATIONS
37	Mainstreamed genetic testing for women with ovarian cancer: first-year experience. <i>Journal of Medical Genetics</i> , 2019, 56, 195-198.	3.2	48
38	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	7.1	44
39	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 53-60.	1.4	40
40	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110398.	3.2	36
41	Tumor Markers in Ovarian Malignancies. <i>Oncologist</i> , 1997, 2, 324-329.	3.7	34
42	British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 695-700.	2.5	34
43	High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). <i>Annals of Oncology</i> , 2001, 12, 693-699.	1.2	32
44	First-line treatment of ovarian cancer: questions and controversies to address. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876823.	3.2	32
45	Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3183-3191.	1.6	29
46	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	1.6	28
47	Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease. <i>Gynecologic Oncology Reports</i> , 2016, 18, 22-24.	0.6	27
48	PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. <i>British Journal of Cancer</i> , 2015, 113, S10-S16.	6.4	25
49	Combining conventional therapy with immunotherapy: A risky business?. <i>European Journal of Cancer</i> , 2019, 113, 41-44.	2.8	25
50	Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. <i>Cancer</i> , 2017, 123, 2752-2761.	4.1	24
51	Maintenance therapy in ovarian cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 521-528.	2.4	23
52	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 969-977.	10.7	23
53	ICON 9 – an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 134-138.	2.5	21
54	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5533-5533.	1.6	20

#	ARTICLE	IF	CITATIONS
55	A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2020, 159, 692-698.	1.4	18
56	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020, 5, e000827.	4.5	18
57	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 125, 1666-1676.	6.4	18
58	Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. <i>ESMO Open</i> , 2021, 6, 100043.	4.5	16
59	An overview of early investigational therapies for chemoresistant ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1163-1183.	4.1	15
60	Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 761-768.	2.5	15
61	Tumor Markers in Ovarian Malignancies. <i>Oncologist</i> , 1997, 2, 324-329.	3.7	15
62	Primary Chemotherapy for Inoperable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without Delayed Debulking Surgery. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 566-572.	2.5	14
63	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	1.4	14
64	Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. <i>Cancer</i> , 2021, 127, 2432-2441.	4.1	14
65	Topography of ncam antigenic epitopes recognized by SCLC-cluster-1 antibodies. A consensus view. <i>International Journal of Cancer</i> , 1994, 57, 27-29.	5.1	13
66	Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 221-226.	2.5	13
67	JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9-TPS9.	1.6	13
68	Olaparib maintenance for first-line treatment of ovarian cancer: Will SOLO1 reset the standard of care?. <i>Future Oncology</i> , 2019, 15, 1845-1853.	2.4	12
69	High dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 53-56.	2.5	11
70	Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. <i>Gynecologic Oncology</i> , 2017, 144, 57-60.	1.4	11
71	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond Breast Cancer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020, 32, 442-450.	2.4	10
72	Extending the scope of PARP inhibitors in ovarian cancer. <i>Lancet Oncology</i> , The, 2019, 20, 470-472.	10.7	9

#	ARTICLE	IF	CITATIONS
73	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 78, 64-73.	2.8	9
74	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer, 2021, 154, 190-200.	2.8	9
75	How Should We Manage Patients with "Platinum-Sensitive" Recurrent Ovarian Cancer?. Cancer Investigation, 2004, 22, 2-10.	1.3	8
76	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Clinical Advances in Hematology and Oncology, 2016, 14, 619-27.	0.3	8
77	Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application. Clinical Trials, 2019, 16, 502-511.	1.6	7
78	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer, 2021, 31, 949-958.	2.5	7
79	British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. International Journal of Gynecological Cancer, 2022, 32, 9-14.	2.5	7
80	Novel Approaches to Improve the Treatment of Rare Gynecologic Cancers: Research Opportunities and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e282-e286.	3.8	5
81	The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. Clinical Advances in Hematology and Oncology, 2016, 14, 704-11.	0.3	5
82	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Medicine, 2021, 10, 7162-7173.	2.8	4
83	Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports, 2021, 23, 97.	4.0	3
84	Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition. , 2015, ,		3
85	Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.. Journal of Clinical Oncology, 2018, 36, 5537-5537.	1.6	2
86	The path for medical associations to sponsor trustworthy guidelines: is it feasible?. Journal of the Royal Society of Medicine, 2022, 115, 252-256.	2.0	2
87	Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?. Gynecologic Oncology, 2019, 153, 213-214.	1.4	1
88	Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II.. Journal of Clinical Oncology, 2013, 31, 3532-3532.	1.6	1
89	Maintenance Treatment for Recurrent Ovarian Carcinoma " Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology and Haematology, 2019, 15, 29.	0.0	1
90	Cryptogenic colitis due to occult cytomegalovirus infection. Frontline Gastroenterology, 2011, 2, 57-62.	1.8	0

#	ARTICLE	IF	CITATIONS
91	The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers. <i>Gynecologic Oncology</i> , 2017, 144, 8-10.	1.4	0
92	High-Grade Carcinomas, BRCA Mutations and the Role of PARP Inhibitors. , 2017, , 171-182.		0
93	Testing for homologous recombination deficiency “ does it provide new insights for the use of veliparib?. <i>Gynecologic Oncology</i> , 2022, 164, 243-244.	1.4	0
94	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5544-5544.	1.6	0